Weintraub M S, Eisenberg S, Breslow J L
Laboratory of Biochemical Genetics and Metabolism, Rockefeller University, New York 10021.
Eur J Clin Invest. 1989 Oct;19(5):480-5. doi: 10.1111/j.1365-2362.1989.tb00263.x.
Drugs that inhibit cholesterol synthesis have recently been released for lowering LDL-cholesterol levels. The current study examines the effect of one of these drugs, lovastatin, alone and in combination with cholestyramine on postprandial fat metabolism in five patients with severely elevated LDL-cholesterol and normal triglyceride levels (less than 1.8 mmol l-1) and in five patients with similarly elevated LDL-cholesterol and mildly elevated triglyceride levels (1.8 to 2.7 mmol l-1). In the group of patients with normal triglyceride levels, neither lovastatin alone nor in combination with cholestyramine had any effect on postprandial lipoprotein levels, while profoundly decreasing LDL-cholesterol levels. This provides evidence that LDL and postprandial lipoproteins are cleared by different mechanisms. In the group of five patients with mildly elevated triglyceride levels, in addition to LDL-cholesterol lowering, lovastatin significantly lowered VLDL-cholesterol, fasting triglyceride and postprandial lipoprotein levels. Thus in patients with mild hypertriglyceridaemia, lovastatin may have another favourable effect on the lipoprotein system in addition to LDL-cholesterol lowering.
近期已推出抑制胆固醇合成的药物来降低低密度脂蛋白胆固醇（LDL - 胆固醇）水平。本研究检测了其中一种药物洛伐他汀单独使用以及与考来烯胺联合使用时，对五名LDL - 胆固醇严重升高且甘油三酯水平正常（低于1.8 mmol/L）的患者和五名LDL - 胆固醇同样升高且甘油三酯水平轻度升高（1.8至2.7 mmol/L）的患者餐后脂肪代谢的影响。在甘油三酯水平正常的患者组中，单独使用洛伐他汀或与考来烯胺联合使用，对餐后脂蛋白水平均无影响，但能显著降低LDL - 胆固醇水平。这证明LDL和餐后脂蛋白是通过不同机制清除的。在五名甘油三酯水平轻度升高的患者组中，除降低LDL - 胆固醇外，洛伐他汀还显著降低了极低密度脂蛋白胆固醇、空腹甘油三酯和餐后脂蛋白水平。因此，在轻度高甘油三酯血症患者中，洛伐他汀除降低LDL - 胆固醇外，可能对脂蛋白系统还有另一个有利影响。
